EP2477980A4 - HCV PROTEASE INHIBITORS - Google Patents

HCV PROTEASE INHIBITORS

Info

Publication number: EP2477980A4
Authority: EP; European Patent Office
Prior art keywords: protease inhibitors; hcv protease; hcv; inhibitors; protease
Prior art date: 2009-09-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP09849606.0A

Other languages

German (de)

French (fr)

Other versions

EP2477980A1 (en

EP2477980B1 (en

Inventor

Chen-Fu Liu

Kuang-Yuan Lee

Pei-Chin Cheng

Yo-Chin Liu

Pin Lo

Kuo-Feng Tseng

Chih-Ming Chen

Chi-Hsin Richard King

Chu-Chung Lin

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

TaiGen Biotechnology Co Ltd

Original Assignee

TaiGen Biotechnology Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-09-15

Filing date

2009-09-15

Publication date

2013-05-01

2009-09-15 Application filed by TaiGen Biotechnology Co Ltd filed Critical TaiGen Biotechnology Co Ltd

2009-09-15 Priority to SI200931505A priority Critical patent/SI2477980T1/en

2009-09-15 Priority to PL09849606T priority patent/PL2477980T3/en

2009-09-15 Priority to HRP20161025TT priority patent/HRP20161025T1/en

2012-07-25 Publication of EP2477980A1 publication Critical patent/EP2477980A1/en

2013-05-01 Publication of EP2477980A4 publication Critical patent/EP2477980A4/en

2016-06-08 Application granted granted Critical

2016-06-08 Publication of EP2477980B1 publication Critical patent/EP2477980B1/en

Status Active legal-status Critical Current

2029-09-15 Anticipated expiration legal-status Critical

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Oncology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

EP09849606.0A 2009-09-15 2009-09-15 Hcv protease inhibitors Active EP2477980B1 (en)

Priority Applications (3)

Application Number	Priority Date	Filing Date	Title
SI200931505A SI2477980T1 (en)	2009-09-15	2009-09-15	Hcv protease inhibitors
PL09849606T PL2477980T3 (en)	2009-09-15	2009-09-15	Hcv protease inhibitors
HRP20161025TT HRP20161025T1 (en)	2009-09-15	2009-09-15	HCV PROTEASE INHIBITORS

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US2009/056937 WO2011034518A1 (en)	2009-09-15	2009-09-15	Hcv protease inhibitors

Publications (3)

Publication Number	Publication Date
EP2477980A1 EP2477980A1 (en)	2012-07-25
EP2477980A4 true EP2477980A4 (en)	2013-05-01
EP2477980B1 EP2477980B1 (en)	2016-06-08

Family

ID=43758907

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP09849606.0A Active EP2477980B1 (en)	2009-09-15	2009-09-15	Hcv protease inhibitors

Country Status (21)

Country	Link
US (1)	US8389560B2 (en)
EP (1)	EP2477980B1 (en)
JP (1)	JP5702388B2 (en)
KR (1)	KR101670319B1 (en)
AU (1)	AU2009352688B2 (en)
CA (1)	CA2774145C (en)
CY (1)	CY1118136T1 (en)
DK (1)	DK2477980T3 (en)
EA (1)	EA022118B1 (en)
ES (1)	ES2588204T3 (en)
HR (1)	HRP20161025T1 (en)
HU (1)	HUE030402T2 (en)
LT (1)	LT2477980T (en)
NZ (1)	NZ599133A (en)
PL (1)	PL2477980T3 (en)
PT (1)	PT2477980T (en)
SG (1)	SG179566A1 (en)
SI (1)	SI2477980T1 (en)
SM (1)	SMT201600291B (en)
WO (1)	WO2011034518A1 (en)
ZA (1)	ZA201202631B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UY32099A (en)	2008-09-11	2010-04-30	Enanta Pharm Inc	HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS
KR20110075019A (en) *	2008-10-15	2011-07-05	인터뮨, 인크.	Therapeutic Antiviral Peptides
CN102741270B (en) *	2009-09-28	2015-07-22	英特穆恩公司	Cyclic peptide inhibitors of hepatitis C virus replication
US20110082182A1 (en) *	2009-10-01	2011-04-07	Intermune, Inc.	Therapeutic antiviral peptides
US20110178107A1 (en) *	2010-01-20	2011-07-21	Taigen Biotechnology Co., Ltd.	Hcv protease inhibitors
KR20140003521A (en)	2010-12-30	2014-01-09	이난타 파마슈티칼스, 인코포레이티드	Phenanthridine macrocyclic hepatitis c serine protease inhibitors
EP2658859A4 (en)	2010-12-30	2014-07-30	Enanta Pharm Inc	Macrocyclic hepatitis c serine protease inhibitors
US8957203B2 (en)	2011-05-05	2015-02-17	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US10201584B1 (en)	2011-05-17	2019-02-12	Abbvie Inc.	Compositions and methods for treating HCV
CN102911254A (en) *	2011-08-02	2013-02-06	上海唐润医药科技有限公司	HCV (hepatitis C virus) protease inhibitor
CA2863002A1 (en)	2012-01-11	2013-07-18	Abbvie Inc.	Processes for making hcv protease inhibitors
KR102127406B1 (en)	2012-09-20	2020-06-29	유디씨 아일랜드 리미티드	Azadibenzofurans for electronic applications
EP2903988A1 (en)	2012-10-08	2015-08-12	AbbVie Inc.	Compounds useful for making hcv protease inhibitors
EA025560B1 (en)	2012-10-19	2017-01-30	Бристол-Майерс Сквибб Компани	Hepatitis c virus inhibitors
WO2014070964A1 (en)	2012-11-02	2014-05-08	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
US9643999B2 (en)	2012-11-02	2017-05-09	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2014071007A1 (en)	2012-11-02	2014-05-08	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
EP2914614B1 (en)	2012-11-05	2017-08-16	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
WO2014137869A1 (en)	2013-03-07	2014-09-12	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
CN104557954A (en) *	2013-10-16	2015-04-29	上海唐润医药科技有限公司	Anti-HCV (hepatitis c virus) macrocyclic compound
EP3089757A1 (en)	2014-01-03	2016-11-09	AbbVie Inc.	Solid antiviral dosage forms
CN104447952A (en) *	2014-12-11	2015-03-25	上海唐润医药科技有限公司	Hepatitis C virus protease inhibitor and synthesis method thereof
CN105859748B (en) *	2015-02-05	2018-06-08	爱博新药研发(上海)有限公司	Polycyclic compound sodium salt and its polymorph, preparation method and application
CN109311904B (en) *	2016-06-22	2022-03-29	出光兴产株式会社	Certain substituted benzofuro-and benzothienoquinolines for use in organic light emitting diodes
US10004719B1 (en) *	2017-05-30	2018-06-26	Taigen Biotechnology Co., Ltd.	Solid dispersion formulation
WO2018222172A1 (en) *	2017-05-30	2018-12-06	Taigen Biotechnology Co., Ltd.	Solid dispersion formulation
US11458386B2 (en) *	2020-02-14	2022-10-04	Valve Corporation	Controller with adjustable features
US12083099B2 (en)	2020-10-28	2024-09-10	Accencio LLC	Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008022006A2 (en) *	2006-08-11	2008-02-21	Enanta Pharmaceuticals, Inc.	Arylalkoxyl hepatitis c virus protease inhibitors
US20090005387A1 (en) *	2007-06-26	2009-01-01	Deqiang Niu	Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
WO2009055335A2 (en) *	2007-10-25	2009-04-30	Taigen Biotechnology Co., Ltd.	Hcv protease inhibitors

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4555508A (en) *	1984-03-02	1985-11-26	Usv Pharmaceutical Corp.	Antihypertensive spiro-cyclic compounds
EP0907659A1 (en)	1996-05-10	1999-04-14	Schering Corporation	Synthetic inhibitors of hepatitis c virus ns3 protease
US5990276A (en)	1996-05-10	1999-11-23	Schering Corporation	Synthetic inhibitors of hepatitis C virus NS3 protease
US5876984A (en) *	1996-09-25	1999-03-02	Shionogi & Co., Ltd	Sequiterpene derivatives having antiviral activity
AP1019A (en)	1996-10-18	2001-10-16	Vertex Pharma	Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease.
GB9707659D0 (en)	1997-04-16	1997-06-04	Peptide Therapeutics Ltd	Hepatitis C NS3 Protease inhibitors
EP1012180B1 (en)	1997-08-11	2004-12-01	Boehringer Ingelheim (Canada) Ltd.	Hepatitis c inhibitor peptide analogues
DK1066247T3 (en)	1998-03-31	2007-04-02	Vertex Pharma	Inhibitors of serine proteases, especially hepatitis C virus NS3 protease
US6323180B1 (en) *	1998-08-10	2001-11-27	Boehringer Ingelheim (Canada) Ltd	Hepatitis C inhibitor tri-peptides
US7244721B2 (en)	2000-07-21	2007-07-17	Schering Corporation	Peptides as NS3-serine protease inhibitors of hepatitis C virus
SV2003000617A (en) *	2000-08-31	2003-01-13	Lilly Co Eli	INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M
US20030073618A1 (en)	2001-02-08	2003-04-17	Kozhemyakin Leonid A.	Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof
US20020182647A1 (en)	2001-04-30	2002-12-05	Emmert-Buck Michael R.	Histoscreen method
IL159087A0 (en) *	2001-07-11	2004-05-12	Vertex Pharma	Bridged bicyclic compounds and pharmaceutical compositions containing the same
US6867185B2 (en) *	2001-12-20	2005-03-15	Bristol-Myers Squibb Company	Inhibitors of hepatitis C virus
CN100352819C (en) *	2002-01-23	2007-12-05	先灵公司	Novel compounds as NS3-serine protease inhibitors of hepatitis c virus
US7119072B2 (en) *	2002-01-30	2006-10-10	Boehringer Ingelheim (Canada) Ltd.	Macrocyclic peptides active against the hepatitis C virus
AU2003223602B8 (en)	2002-04-11	2010-05-27	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases, particularly hepatitis C virus NS3-NS4 protease
DE60324552D1 (en) *	2002-05-20	2008-12-18	Bristol Myers Squibb Co	Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
MY140680A (en)	2002-05-20	2010-01-15	Bristol Myers Squibb Co	Hepatitis c virus inhibitors
US7601367B2 (en)	2002-05-28	2009-10-13	Mirus Bio Llc	Compositions and processes using siRNA, amphipathic compounds and polycations
EP2361913A1 (en)	2002-11-01	2011-08-31	Abbott Laboratories	Anti-infective agents
CA2515216A1 (en)	2003-02-07	2004-08-26	Enanta Pharmaceuticals, Inc.	Macrocyclic hepatitis c serine protease inhibitors
WO2004092161A1 (en)	2003-04-11	2004-10-28	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
EP1636208B1 (en)	2003-04-11	2012-02-29	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
ES2320771T3 (en)	2003-04-16	2009-05-28	Bristol-Myers Squibb Company	PEPTIDIC INHIBITORS OF MACROCICLIC ISOQUINOLINE VIRUS OF HEPATITIS C.
US7176208B2 (en) *	2003-04-18	2007-02-13	Enanta Pharmaceuticals, Inc.	Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
MXPA05013658A (en)	2003-06-11	2006-03-02	Hybridon Inc	Stabilized immunomodulatory oligonucleotides.
EP1646642A2 (en)	2003-07-18	2006-04-19	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
WO2005028502A1 (en)	2003-09-18	2005-03-31	Vertex Pharmaceuticals, Incorporated	Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
RS20060197A (en)	2003-09-22	2008-09-29	Boehringer Ingelheim International Gmbh.,	Macrocyclic peptides active against the hepatitis c virus
JP4525982B2 (en) *	2003-09-26	2010-08-18	シェーリングコーポレイション	Macrocyclic inhibitor of NS3 serine protease of hepatitis C virus
US7491794B2 (en) *	2003-10-14	2009-02-17	Intermune, Inc.	Macrocyclic compounds as inhibitors of viral replication
JP2007532479A (en) *	2003-11-20	2007-11-15	シェーリング　コーポレイション	Depeptideization inhibitor of hepatitis C virus NS3 protease
BRPI0416902A (en) *	2003-12-11	2007-01-16	Schering Corp	hepatitis c virus ns3 / ns4a serine protease inhibitors
EP1730167B1 (en)	2004-01-21	2011-01-12	Boehringer Ingelheim International GmbH	Macrocyclic peptides active against the hepatitis c virus
US7375218B2 (en) *	2004-09-17	2008-05-20	Boehringer Ingelheim International Gmbh	Process for preparing macrocyclic HCV protease inhibitors
US20070207949A1 (en) *	2005-06-02	2007-09-06	Anima Ghosal	Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
JP2008545748A (en)	2005-06-02	2008-12-18	シェーリングコーポレイション	Sustained release formulations useful for treating disorders associated with hepatitis C virus
US20070237818A1 (en) *	2005-06-02	2007-10-11	Malcolm Bruce A	Controlled-release formulation of HCV protease inhibitor and methods using the same
AR061629A1 (en)	2006-06-26	2008-09-10	Enanta Pharm Inc	QUINOXALINIL MACROCICLIC INHIBITORS OF SERINE PROTEASE OF HEPATITIS VIRUS C. PROCESS OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS
US7605126B2 (en) *	2006-08-11	2009-10-20	Enanta Pharmaceuticals, Inc.	Acylaminoheteroaryl hepatitis C virus protease inhibitors
US20080267917A1 (en) *	2007-04-26	2008-10-30	Deqiang Niu	N-functionalized amides as hepatitis c serine protease inhibitors
US20080274080A1 (en) *	2007-04-26	2008-11-06	Yat Sun Or	Aza-peptide macrocyclic hepatitis c serine protease inhibitors

2009
- 2009-09-15 PL PL09849606T patent/PL2477980T3/en unknown
- 2009-09-15 US US12/559,818 patent/US8389560B2/en not_active Expired - Fee Related
- 2009-09-15 SG SG2012018412A patent/SG179566A1/en unknown
- 2009-09-15 EA EA201270423A patent/EA022118B1/en unknown
- 2009-09-15 AU AU2009352688A patent/AU2009352688B2/en not_active Ceased
- 2009-09-15 LT LTEP09849606.0T patent/LT2477980T/en unknown
- 2009-09-15 KR KR1020127009259A patent/KR101670319B1/en not_active Expired - Fee Related
- 2009-09-15 JP JP2012529723A patent/JP5702388B2/en not_active Expired - Fee Related
- 2009-09-15 PT PT98496060T patent/PT2477980T/en unknown
- 2009-09-15 HU HUE09849606A patent/HUE030402T2/en unknown
- 2009-09-15 DK DK09849606.0T patent/DK2477980T3/en active
- 2009-09-15 ES ES09849606.0T patent/ES2588204T3/en active Active
- 2009-09-15 EP EP09849606.0A patent/EP2477980B1/en active Active
- 2009-09-15 CA CA2774145A patent/CA2774145C/en not_active Expired - Fee Related
- 2009-09-15 HR HRP20161025TT patent/HRP20161025T1/en unknown
- 2009-09-15 WO PCT/US2009/056937 patent/WO2011034518A1/en not_active Ceased
- 2009-09-15 SI SI200931505A patent/SI2477980T1/en unknown
- 2009-09-15 NZ NZ599133A patent/NZ599133A/en not_active IP Right Cessation
2012
- 2012-04-12 ZA ZA2012/02631A patent/ZA201202631B/en unknown
2016
- 2016-08-29 SM SM201600291T patent/SMT201600291B/en unknown
- 2016-08-31 CY CY20161100856T patent/CY1118136T1/en unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008022006A2 (en) *	2006-08-11	2008-02-21	Enanta Pharmaceuticals, Inc.	Arylalkoxyl hepatitis c virus protease inhibitors
US20090005387A1 (en) *	2007-06-26	2009-01-01	Deqiang Niu	Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
WO2009055335A2 (en) *	2007-10-25	2009-04-30	Taigen Biotechnology Co., Ltd.	Hcv protease inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2011034518A1 *

Also Published As

Publication number	Publication date
EA201270423A1 (en)	2012-09-28
DK2477980T3 (en)	2016-09-12
NZ599133A (en)	2013-10-25
US8389560B2 (en)	2013-03-05
SMT201600291B (en)	2016-11-10
JP2013504616A (en)	2013-02-07
JP5702388B2 (en)	2015-04-15
HRP20161025T1 (en)	2016-11-04
PT2477980T (en)	2016-08-31
ES2588204T3 (en)	2016-10-31
AU2009352688B2 (en)	2014-04-17
KR20120110091A (en)	2012-10-09
WO2011034518A1 (en)	2011-03-24
EA022118B1 (en)	2015-11-30
EP2477980A1 (en)	2012-07-25
CY1118136T1 (en)	2017-06-28
AU2009352688A1 (en)	2012-04-26
KR101670319B1 (en)	2016-10-28
EP2477980B1 (en)	2016-06-08
ZA201202631B (en)	2012-12-27
PL2477980T3 (en)	2017-02-28
SG179566A1 (en)	2012-05-30
LT2477980T (en)	2016-09-26
CA2774145C (en)	2015-10-27
US20110065737A1 (en)	2011-03-17
HUE030402T2 (en)	2017-05-29
CA2774145A1 (en)	2011-03-24
SI2477980T1 (en)	2017-01-31

Legal Events

Date	Code	Title	Description
2012-06-22	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2012-07-25	17P	Request for examination filed	Effective date: 20120403
2012-07-25	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
2012-12-19	DAX	Request for extension of the european patent (deleted)
2013-05-01	A4	Supplementary search report drawn up and despatched	Effective date: 20130403
2013-05-01	RIC1	Information provided on ipc code assigned before grant	Ipc: C07D 401/12 20060101ALI20130326BHEP Ipc: C07K 5/08 20060101ALI20130326BHEP Ipc: A61P 31/12 20060101ALI20130326BHEP Ipc: A61K 31/4355 20060101ALI20130326BHEP Ipc: C07D 403/12 20060101AFI20130326BHEP
2015-11-29	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2015-12-16	RIC1	Information provided on ipc code assigned before grant	Ipc: C07D 491/048 20060101ALI20151110BHEP Ipc: A61K 31/4355 20060101ALI20151110BHEP Ipc: C07D 403/12 20060101AFI20151110BHEP Ipc: A61K 38/06 20060101ALI20151110BHEP Ipc: C07K 5/083 20060101ALI20151110BHEP Ipc: C07D 519/00 20060101ALI20151110BHEP Ipc: A61K 31/519 20060101ALI20151110BHEP Ipc: C07D 401/12 20060101ALI20151110BHEP Ipc: C07K 5/08 20060101ALI20151110BHEP Ipc: A61P 31/12 20060101ALI20151110BHEP
2015-12-30	INTG	Intention to grant announced	Effective date: 20151130
2016-04-08	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2016-05-04	GRAR	Information related to intention to grant a patent recorded	Free format text: ORIGINAL CODE: EPIDOSNIGR71
2016-05-06	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2016-06-08	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
2016-06-08	INTG	Intention to grant announced	Effective date: 20160503
2016-06-08	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2016-06-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2016-06-29	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2016-07-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 805144 Country of ref document: AT Kind code of ref document: T Effective date: 20160715
2016-07-21	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602009039183 Country of ref document: DE
2016-08-16	REG	Reference to a national code	Ref country code: HR Ref legal event code: TUEP Ref document number: P20161025 Country of ref document: HR
2016-08-30	REG	Reference to a national code	Ref country code: RO Ref legal event code: EPE
2016-08-31	REG	Reference to a national code	Ref country code: PT Ref legal event code: SC4A Ref document number: 2477980 Country of ref document: PT Date of ref document: 20160831 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20160824 Ref country code: NL Ref legal event code: FP
2016-09-12	REG	Reference to a national code	Ref country code: DK Ref legal event code: T3 Effective date: 20160909
2016-09-20	REG	Reference to a national code	Ref country code: SE Ref legal event code: TRGR
2016-09-26	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 8
2016-10-17	REG	Reference to a national code	Ref country code: EE Ref legal event code: FG4A Ref document number: E012336 Country of ref document: EE Effective date: 20160818
2016-10-31	REG	Reference to a national code	Ref country code: NO Ref legal event code: T2 Effective date: 20160608 Ref country code: ES Ref legal event code: FG2A Ref document number: 2588204 Country of ref document: ES Kind code of ref document: T3 Effective date: 20161031
2016-11-04	REG	Reference to a national code	Ref country code: HR Ref legal event code: T1PR Ref document number: P20161025 Country of ref document: HR
2017-02-02	REG	Reference to a national code	Ref country code: GR Ref legal event code: EP Ref document number: 20160402071 Country of ref document: GR Effective date: 20161118
2017-03-09	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602009039183 Country of ref document: DE
2017-04-14	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2017-04-14	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2017-05-17	26N	No opposition filed	Effective date: 20170309
2017-05-29	REG	Reference to a national code	Ref country code: HU Ref legal event code: AG4A Ref document number: E030402 Country of ref document: HU
2017-09-25	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9
2018-09-25	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10
2019-01-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: UEP Ref document number: 805144 Country of ref document: AT Kind code of ref document: T Effective date: 20160608
2019-10-04	REG	Reference to a national code	Ref country code: HR Ref legal event code: ODRP Ref document number: P20161025 Country of ref document: HR Payment date: 20190909 Year of fee payment: 11
2020-07-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: NO Payment date: 20200520 Year of fee payment: 12
2020-08-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: SE Payment date: 20200519 Year of fee payment: 12
2020-10-02	REG	Reference to a national code	Ref country code: HR Ref legal event code: ODRP Ref document number: P20161025 Country of ref document: HR Payment date: 20200903 Year of fee payment: 12
2020-10-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: MC Payment date: 20200921 Year of fee payment: 12 Ref country code: SK Payment date: 20200826 Year of fee payment: 12 Ref country code: SM Payment date: 20200922 Year of fee payment: 12 Ref country code: LU Payment date: 20200925 Year of fee payment: 12 Ref country code: DK Payment date: 20200925 Year of fee payment: 12 Ref country code: FI Payment date: 20200918 Year of fee payment: 12 Ref country code: IS Payment date: 20200924 Year of fee payment: 12
2020-11-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: LV Payment date: 20200922 Year of fee payment: 12 Ref country code: MK Payment date: 20200826 Year of fee payment: 12 Ref country code: AT Payment date: 20200918 Year of fee payment: 12 Ref country code: SI Payment date: 20200825 Year of fee payment: 12
2020-12-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: MT Payment date: 20200923 Year of fee payment: 12
2021-01-29	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CY Payment date: 20200902 Year of fee payment: 12
2021-07-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20210630 Year of fee payment: 13 Ref country code: PT Payment date: 20210629 Year of fee payment: 13
2021-08-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IE Payment date: 20210629 Year of fee payment: 13
2021-09-17	REG	Reference to a national code	Ref country code: HR Ref legal event code: ODRP Ref document number: P20161025 Country of ref document: HR Payment date: 20210831 Year of fee payment: 13
2021-10-29	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CH Payment date: 20210923 Year of fee payment: 13 Ref country code: CZ Payment date: 20210915 Year of fee payment: 13 Ref country code: EE Payment date: 20210921 Year of fee payment: 13 Ref country code: BG Payment date: 20210921 Year of fee payment: 13 Ref country code: NL Payment date: 20210927 Year of fee payment: 13 Ref country code: LT Payment date: 20210826 Year of fee payment: 13 Ref country code: HR Payment date: 20210831 Year of fee payment: 13 Ref country code: IT Payment date: 20210923 Year of fee payment: 13
2021-11-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: BE Payment date: 20210927 Year of fee payment: 13 Ref country code: TR Payment date: 20210826 Year of fee payment: 13 Ref country code: RO Payment date: 20210831 Year of fee payment: 13 Ref country code: GR Payment date: 20210921 Year of fee payment: 13 Ref country code: HU Payment date: 20210825 Year of fee payment: 13 Ref country code: PL Payment date: 20210902 Year of fee payment: 13 Ref country code: DE Payment date: 20210630 Year of fee payment: 13 Ref country code: GB Payment date: 20210701 Year of fee payment: 13
2022-01-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: ES Payment date: 20211012 Year of fee payment: 13
2022-04-13	REG	Reference to a national code	Ref country code: FI Ref legal event code: MAE
2022-04-25	REG	Reference to a national code	Ref country code: NO Ref legal event code: MMEP
2022-04-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210915
2022-05-02	REG	Reference to a national code	Ref country code: DK Ref legal event code: EBP Effective date: 20210930
2022-05-03	REG	Reference to a national code	Ref country code: SE Ref legal event code: EUG
2022-05-11	REG	Reference to a national code	Ref country code: SK Ref legal event code: MM4A Ref document number: E 21886 Country of ref document: SK Effective date: 20210915
2022-05-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MM01 Ref document number: 805144 Country of ref document: AT Kind code of ref document: T Effective date: 20210915
2022-06-01	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210930 Ref country code: LV Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210915 Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210915
2022-06-30	REG	Reference to a national code	Ref country code: SI Ref legal event code: KO00 Effective date: 20220520
2022-07-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SM Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220411 Ref country code: SK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210915 Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210916 Ref country code: NO Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210930 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210915
2022-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210915
2022-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210930
2023-03-23	REG	Reference to a national code	Ref country code: HR Ref legal event code: PBON Ref document number: P20161025 Country of ref document: HR Effective date: 20220915
2023-04-01	REG	Reference to a national code	Ref country code: DE Ref legal event code: R119 Ref document number: 602009039183 Country of ref document: DE
2023-04-11	REG	Reference to a national code	Ref country code: LT Ref legal event code: MM4D Effective date: 20220915
2023-04-17	REG	Reference to a national code	Ref country code: EE Ref legal event code: MM4A Ref document number: E012336 Country of ref document: EE Effective date: 20220930
2023-04-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: RO Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220915 Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230315 Ref country code: CZ Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220915
2023-04-28	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2023-05-03	REG	Reference to a national code	Ref country code: NL Ref legal event code: MM Effective date: 20221001
2023-05-24	GBPC	Gb: european patent ceased through non-payment of renewal fee	Effective date: 20220915
2023-05-25	REG	Reference to a national code	Ref country code: BE Ref legal event code: MM Effective date: 20220930
2023-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221001
2023-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220915 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220930 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220915 Ref country code: HU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220916 Ref country code: HR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220915 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220930 Ref country code: EE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220930 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230401 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220930
2023-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230406
2023-09-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220930
2023-10-27	REG	Reference to a national code	Ref country code: ES Ref legal event code: FD2A Effective date: 20231027
2023-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220915 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220915
2023-11-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220915
2024-01-22	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220916
2024-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220916
2024-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BG Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220915
2024-08-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210915
2024-09-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220915
2025-10-16	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IS Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220404

Publication	Publication Date	Title
EP2477980A4 (en)	2013-05-01	HCV PROTEASE INHIBITORS
EP2618665A4 (en)	2014-08-20	HCV NS3 PROTEASE INHIBITORS
LTPA2017010I1 (en)	2017-05-10	Protease inhibitors
EP2271345A4 (en)	2011-08-31	HCV NS3 PROTEASE INHIBITORS
BRPI0807547A2 (en)	2014-06-17	HYPERCYCLIC ASPARTIL PROTEASE INHIBITORS
DK2408758T3 (en)	2014-12-01	Crystalline tripeptide epoxy-ketone protease inhibitors
ZA201008988B (en)	2012-01-25	Hcv protease inhibitors
BRPI0923184A2 (en)	2019-09-24	hcv ns3 protease inhibitors
DK2373172T3 (en)	2013-10-21	HCV NS5A INHIBITORS
BRPI0922084A2 (en)	2015-01-27	COMPOSITIONS AND METHODS UNDERSTANDING SERINA PROTEASE VARIANTS
BRPI1011267A2 (en)	2016-03-22	protease inhibitors
BR112012005438A2 (en)	2018-03-20	flaviviridae virus inhibitors
EP2740734A4 (en)	2015-03-11	HCV PROTEASE INHIBITORS
DK3346004T3 (en)	2020-02-17	AMYLASE POLYPEPTIDER
DK2459906T3 (en)	2015-04-20	Sealing
BR112012005382A2 (en)	2016-03-29	jak inhibitors
EP2432318A4 (en)	2012-11-21	Bimacrocyclic hcv ns3 protease inhibitors
DK2394340T4 (en)	2019-10-21	sealing
BRPI1010661A2 (en)	2016-03-15	peptide
BR112013010836A2 (en)	2019-09-24	hcv ns3 protease specific inhibitors
EP2313426A4 (en)	2012-01-18	Novel protease inhibitors
BRPI0918966A2 (en)	2015-12-01	protease inhibitors
BRPI0919073A2 (en)	2016-03-15	protease inhibitors
EP2400976A4 (en)	2012-08-08	SOFTENING PROTEASE INHIBITORS AND PRO-SOFTENING FORMS THEREOF
SG2014011258A (en)	2014-07-30	Hcv protease inhibitors